BioVaxys Provides Viral Vaccine Platform Program Update
Vancouver, BC, Dec 1, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (“BioVaxys” or “the Company”) is pleased to announce that it has received further data […]
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today […]